Nektar pulls pain drug after bruising FDA panel meetingNektar Therapeutics has opted to withdraw its marketing application for new opioid painkiller oxycodegol after an FDA advisory Share XNektar pulls pain drug after bruising FDA panel meetinghttps://pharmaphorum.com/news/nektar-pulls-pain-drug-after-bruising-fda-panel-meeting/
Nektar, BioMarin, and Alnylam top list of biotech M&A targetsWith Takeda’s £46 billion acquisition of Shire, it’s been a busy year for pharma M&A – and according Share XNektar, BioMarin, and Alnylam top list of biotech M&A targetshttps://pharmaphorum.com/news/nektar-biomarin-and-alnylam-top-list-of-biotech-ma-targets/
BMS makes record $1.8bn bet on Nektar cancer drugBristol-Myers Squibb scored a first-in-class approval with cancer immunotherapy Opdivo just a few years ago – could it Share XBMS makes record $1.8bn bet on Nektar cancer drughttps://pharmaphorum.com/news/bms-makes-record-1-8bn-bet-on-nektar-cancer-drug/
BMS and Nektar to pair Opdivo with natural killer cell drugBMS and Nektar’s combination latest in frenzied immunotherapy field Share XBMS and Nektar to pair Opdivo with natural killer cell drughttps://pharmaphorum.com/news/bms-nektar-pair-opdivo-natural-killer-cell-drug/